Mina C. Hosseinipour
University of North Carolina at Chapel Hill
378 Papers
1.7K Citations
Mina C. Hosseinipour is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 48, co-authored 333 publications. Previous affiliations of Mina C. Hosseinipour include University of Malawi & Kamuzu Central Hospital.
Chat about Author
Papers
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine
Albert Mwafongo,Kondwani Nkanaunena,Yu Zheng,Evelyn Hogg,Wadzanai Samaneka,Lloyd Mulenga,Abraham Siika,Judith S. Currier,Shahin Lockman,Michael Hughes,Mina C. Hosseinipour +10 more
TL;DR: Patients taking TDF co-administered with LPV/r had significantly more renal events compared to those co- Administered with NVP, and higher baseline HIV RNA and lower creatinine clearance were associated with the development of renal insufficiency requiring treatment modification.
Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort
Ashwin Balagopal,Nikhil Gupte,Rupak Shivakoti,Andrea L. Cox,Wei-Teng Yang,Sima Berendes,Noluthando Mwelase,Cecilia Kanyama,Sandy Pillay,Wadzanai Samaneka,Breno Santos,Selvamuthu Poongulali,Srikanth Tripathy,Cynthia Riviere,Javier R. Lama,Sandra W. Cardoso,Patcharaphan Sugandhavesa,Richard D. Semba,James Hakim,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,Ian Sanne,David M. Asmuth,Thomas B. Campbell,Robert C. Bollinger,Amita Gupta +25 more
TL;DR: Continued IL-18 and sCD14 elevations were associated with clinical ART failure, and IFN-γ levels may reflect preserved immune function, which is associated with protection from failure.
"The Drug Will Help Protect My Tomorrow": Perceptions of Integrating PrEP into HIV Prevention Behaviors Among Female Sex Workers in Lilongwe, Malawi.
Jaclyn M Shea,Agatha Bula,Wezzie Dunda,Mina C. Hosseinipour,Carol E. Golin,Irving F. Hoffman,William C. Miller,Vivian F. Go,Thandie Lungu,Kathryn E. Lancaster +9 more
TL;DR: Focus group discussions were conducted with 44 HIV-negative FSW in Lilongwe, Malawi to explore perceptions of PrEP: acceptability, integration within HIV prevention behaviors, and barriers to use.
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial
Rami Kantor,Laura M. Smeaton,Saran Vardhanabhuti,Sarah E. Hudelson,Carol L. Wallis,Srikanth Tripathy,Mariza G. Morgado,Shanmugham Saravanan,Pachamuthu Balakrishnan,Marissa B Reitsma,Stephen Hart,John W. Mellors,Elias K. Halvas,Beatriz Grinsztejn,Mina C. Hosseinipour,Johnstone Kumwenda,Alberto La Rosa,Umesh G. Lalloo,Javier R. Lama,Mohammed Rassool,Breno Santos,Khuanchai Supparatpinyo,James Hakim,Timothy P. Flanigan,Nagalingeswaran Kumarasamy,Thomas B. Campbell,Susan H. Eshleman +26 more
TL;DR: In this global clinical trial, pretreatment resistance and HIV-1 subtype were independently associated with virologic failure and should be considered whenever feasible.
Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission
Charles Chasela,Michael G. Hudgens,Denise J. Jamieson,Dumbani Kayira,Mina C. Hosseinipour,Athena P. Kourtis,Francis Martinson,Gerald Tegha,Rodney J. Knight,Yusuf Ahmed,Deborah Kamwendo,Irving F. Hoffman,Sascha R. Ellington,Zebrone Kacheche,Alice Soko,Jeffrey Wiener,Susan A. Fiscus,Peter N. Kazembe,Innocent Mofolo,Maggie Chigwenembe,Dorothy Sichali,Charles van der Horst +21 more
TL;DR: The use of either a maternal antiretroviral regimen or infant nevirapine for 28 weeks was effective in reducing HIV-1 transmission during breast-feeding.